Research progress on application of radiotherapy to sensitize PD-1/PD-L1 inhibitors
10.3760/cma.j.cn113030-20201119-00559
- VernacularTitle:放疗增敏PD-1/PD-L1抑制剂疗效的研究进展
- Author:
Yuehong KONG
1
;
Yifu MA
;
Xiangrong ZHAO
;
Liyuan ZHANG
Author Information
1. 苏州大学附属第二医院放疗科 苏州大学附属第二医院肿瘤放射免疫治疗实验室 苏州市肿瘤放射免疫治疗重点实验室 215104
- Keywords:
PD-1/PD-L1 inhibitor;
Neoplasm/radiotherapy;
Neoplasm/immunotherapy;
Radiotherapy enhancement
- From:
Chinese Journal of Radiation Oncology
2021;30(9):984-988
- CountryChina
- Language:Chinese
-
Abstract:
Programmed cell death-1/programmed cell death-ligand 1(PD-1/PD-L1) inhibitors have been approved for a variety of tumors, whereas the efficacy as monotherapy is low. How to sensitize the efficacy of PD-1/PD-L1 inhibitors through combined radiotherapy is the current research focus. Multiple studies have demonstrated that the combination of radiotherapy and anti-PD-1/PD-L1 therapy has yielded survival benefits. Nevertheless, ionizing radiation is a double-edged sword for anti-PD-1/PD-L1 therapy. For patients with metastatic cancers, radiotherapy should be fully exerted as a sensitizer to systemic anti-PD-1/PD-L1 therapy and the immunosuppressive effects should be avoided as much as possible. It is closely correlated with the selection of radiation dose, fraction size, treatment timing and irradiated numbers and sites. Therefore, this article reviews how to optimize radiotherapy combined with anti-PD-1/PD-L1 treatment scheduled for advanced stage metastatic cancers.
